|Print Page Close Window|
|DURECT CORP filed this Form 8-K on 11/19/2018|
On November 19, 2018, DURECT Corporation issued a press release announcing it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits